دورية أكاديمية
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
| العنوان: | Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. |
|---|---|
| المؤلفون: | van Nassau SC; Department of Medical Oncology, Division Cancer Center and Imaging, University Medical Center Utrecht, Utrecht, the Netherlands., Bond MJ; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Scheerman I; Department of Medical Oncology, Division Cancer Center and Imaging, University Medical Center Utrecht, Utrecht, the Netherlands., van Breeschoten J; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Kessels R; Dutch Oncology Research Platform, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Valkenburg-van Iersel LB; Division of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Verheul HM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mekenkamp LJ; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, the Netherlands., Lemmens VE; Board of Directors, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.; Department of Public Health, Erasmus University Medical Centre, Rotterdam, the Netherlands., Koopman M; Department of Medical Oncology, Division Cancer Center and Imaging, University Medical Center Utrecht, Utrecht, the Netherlands., Bol GM; Department of Medical Oncology, Division Cancer Center and Imaging, University Medical Center Utrecht, Utrecht, the Netherlands. |
| مؤلفون مشاركون: | EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group |
| المصدر: | JAMA network open [JAMA Netw Open] 2021 Sep 01; Vol. 4 (9), pp. e2124766. Date of Electronic Publication: 2021 Sep 01. |
| نوع المنشور: | Evaluation Study; Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago, IL : American Medical Association, [2018]- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Bevacizumab/*administration & dosage , Colorectal Neoplasms/*drug therapy , Drug Prescriptions/*statistics & numerical data , Medical Oncology/*statistics & numerical data , Patient Acceptance of Health Care/*statistics & numerical data, Aged ; Cross-Sectional Studies ; Female ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Netherlands ; Oxaliplatin/administration & dosage ; Research Design |
| مستخلص: | Importance: Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC). However, the degree of implementation of FOLFOXIRI-B in daily practice is unknown. Objectives: To evaluate the current adoption rate of FOLFOXIRI-B in patients with mCRC and investigate the perspectives of medical oncologists toward this treatment option. Design, Setting, and Participants: This 1-week, multicenter, cross-sectional study in the Netherlands used a flash mob design, which facilitates ultrafast data generation (flash) through the engagement of numerous researchers (mob). During the study week (March 1-5, 2021), patient data were retrieved from electronic health records of 47 hospitals on patients with mCRC who were referred to a medical oncologist between November 1, 2020, and January 31, 2021. Interviews were simultaneously conducted with 101 medical oncologists from 52 hospitals who regularly treat patients with mCRC. Exposure: First-line systemic treatment as determined by the treating physician. Main Outcomes and Measures: The FOLFOXIRI-B prescription rate was the main outcome. Current practice was compared with prescription rates in 2015 to 2018. Eligibility for treatment with FOLFOXIRI-B was estimated. An exploratory outcome was medical oncologists' reported perspectives on FOLFOXIRI-B. Results: A total of 5948 patients in the Netherlands (median age [interquartile range], 66 [57-73] years; 3503 [59%] male; and 3712 [62%] with left-sided or rectal tumor) were treated with first-line systemic therapy for synchronous mCRC. A total of 282 patients with mCRC underwent systemic therapy during the study period (2021). Of these 282 patients, 199 (71%) were treated with intensive first-line therapy other than FOLFOXIRI-B, of whom 184 (65%) were treated with oxaliplatin doublets with or without bevacizumab; 14 (5%) with irinotecan doublets with or without bevacizumab, panitumumab, or cetuximab; and 1 (0.4%) with irinotecan with bevacizumab. Fifty-four patients (19%) were treated with fluoropyrimidine monotherapy with or without bevacizumab, 1 patient (0.4%) with panitumumab monotherapy, and 3 (1%) with immune checkpoint inhibitors. In total, 25 patients (9%; 95% CI, 6%-12%) were treated with first-line FOLFOXIRI-B compared with 142 (2%; 95% CI, 2%-3%) in 2015 to 2018. During the study period, 21 of 157 eligible patients (13.4%) in the Netherlands were treated with FOLFOXIRI-B. A total of 87 medical oncologists (86%) reported discussing FOLFOXIRI-B as a treatment option with eligible patients. A total of 47 of 85 (55%) generally communicated a preference for a chemotherapy doublet to patients. These oncologists reported a significantly lower awareness of guidelines and trial results. Toxic effects were the most reported reason to prefer an alternative regimen. Conclusions and Relevance: The findings of this study suggest that FOLFOXIRI-B prescription rates have marginally increased in the last 5 years. Considering that most medical oncologists discuss this treatment option, the prescription rate found in this study was below expectations. Awareness of guidelines and trial data seems to contribute to the discussion of available treatment options by medical oncologists, and the findings of this study suggest a need for repeated and continuing medical education. |
| References: | Br J Cancer. 2010 Jul 13;103(2):159-64. (PMID: 20551951) J Natl Compr Canc Netw. 2017 Mar;15(3):370-398. (PMID: 28275037) Ann Fam Med. 2019 Jul;17(4):296-303. (PMID: 31285206) Chest. 2017 May;151(5):1106-1113. (PMID: 27940191) J R Soc Med. 2011 Dec;104(12):510-20. (PMID: 22179294) Lancet Oncol. 2015 Oct;16(13):1306-15. (PMID: 26338525) Yearb Med Inform. 2000;(1):65-70. (PMID: 27699347) Int J Cancer. 2021 Jan 15;148(2):296-306. (PMID: 32638384) Ann Oncol. 2016 Aug;27(8):1386-422. (PMID: 27380959) JAMA Intern Med. 2018 Sep 1;178(9):1201-1208. (PMID: 30014139) J Clin Oncol. 2020 Aug 20;:JCO2001225. (PMID: 32816630) Eur J Cancer. 2018 Sep;100:35-45. (PMID: 29936065) Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9. (PMID: 25190710) Ned Tijdschr Geneeskd. 2020 May 11;164:. (PMID: 32608930) BMJ. 2000 Apr 22;320(7242):1107-11. (PMID: 10775218) Chest. 2013 Jun;143(6):1740-1744. (PMID: 23197319) Annu Rev Public Health. 2009;30:151-74. (PMID: 19705558) N Engl J Med. 2014 Oct 23;371(17):1609-18. (PMID: 25337750) Bull World Health Organ. 2007 Nov;85(11):867-72. (PMID: 18038077) Clin Adv Hematol Oncol. 2019 Aug;17(8):433-435. (PMID: 31449510) Implement Sci. 2020 Jun 3;15(1):41. (PMID: 32493348) Lancet Oncol. 2020 Apr;21(4):497-507. (PMID: 32164906) Lancet Oncol. 2020 Apr;21(4):468-469. (PMID: 32164907) |
| فهرسة مساهمة: | Investigator: MM Streppel; L van Hout; M Los; Z Hofman; LW Kessels; EHA Groen; LLH van Huis-Tanja; FE de Jongh; LJM Alferink; HMB Otten; EJE Wink-van Gestel; AMT van der Velden; DW Sommeijer; SO Araghi; LM Latten-Jansen; MS Keusters; BCM Haberkorn; AJ Verschoor; C Haazer; GJ Creemers; NFT Henckens; FJF Jeurissen; KEM de Nijs; R Hoekstra; JJ Zwartjens; MP Hendriks; AD van Leeuwen; H van Cruijssen; PT Werner; WECJ Heuts; P Nieboer; NAJB Peters; M van Cranenbroek; T van Voorthuizen; F Terheggen; M Pieters; MPS Sie; LHJ Simkens; JGL Olislagers; ML Wumkes; R Janssen; L Spierings; E van Staveren; I Kats; AH Vos; JJ Heier; EA van Breugel; J Vincent; MA Davidis; T Sepers; JJB Janssen; BBO Broeren; LMH van de Winkel; SA Hiddink; ASB Conijn-Mensink; S van Lunteren; AA van Zweeden; M Vergouwe; BMJ Scholtes; SE Dohmen; M Ijzer; J de Boer; KCJA Punt; GR Vink; PAH Hamers; KC Smit; MA Huismans; EGE Wensink; SJ Schraa; KL van Rooijen; JWG Derksen; AM May; K Zwart; JMJ Roodhart |
| المشرفين على المادة: | 04ZR38536J (Oxaliplatin) 2S9ZZM9Q9V (Bevacizumab) Q573I9DVLP (Leucovorin) U3P01618RT (Fluorouracil) |
| تواريخ الأحداث: | Date Created: 20210910 Date Completed: 20220112 Latest Revision: 20231102 |
| رمز التحديث: | 20231102 |
| مُعرف محوري في PubMed: | PMC8433607 |
| DOI: | 10.1001/jamanetworkopen.2021.24766 |
| PMID: | 34505885 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!